Chemotherapy Treatment in Gastric Cancer
Eric Van Cutsem, MD, PhD, discusses the challenges of using chemotherapy to treat patients with gastric cancer.
Eric Van Cutsem, MD, PhD, at University Hospitals Gasthuisberg/Leuven in Leuven, Belgium, discusses the challenges of using chemotherapy to treat patients with gastric cancer.
Clinical Pearls:
- Using trastuzumab or other anti-HER2 agents when treating patients with gastric cancer does not eliminate the need to use chemotherapy.
- Patients with gastric cancer are often in poor health to begin with and have low tolerance levels and fast occurrances of resistance after undergoing chemotherapy.
- There is room for growth and improvement in chemotherapy in order to determine if the treatments can contain less toxicities, which remains a challenge for patients in regards to their overall means of survival.
Peers Discuss Role of Pola-R-CHP vs R-CHOP in Newly Diagnosed DLBCL
April 19th 2024During a Case-Based Roundtable® event, Haifaa Abdulhaq, MD discussed with participants whether the POLARIX trial influences their choice to use the pola-R-CHP as opposed to R-CHOP regimen for patients with newly diagnosed diffuse large B-cell lymphoma.
Read More
Powell Reviews Updated IO/TKI Data and AE Management in Endometrial Cancer
April 18th 2024During a Case-Based Roundtable® event, Matthew A. Powell, MD, discussed the case of a patient with advanced endometrial cancer treated with lenvatinib plus pembrolizumab who experienced grade 2 treatment-related hypertension.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
